We suppose that treatment with SGLT2i activates starvation-mimicking signalling leading to energy dissipation, including the release of FGF-21, but, in obesity, the extent of this response is limited and not sufficient to counteract the compensatory increase of food intake, thus limiting the drug potential on weight loss. The gene discussed is FGF21; the disease is Obesity.